Prof. Nat Lenzo

Prof Nat Lenzo

Prof Nat Lenzo
BSc BMedSci(Hons) MBBS MSc(Oncol) MMed MHSvMgt EMBA FRACP FAANMS GAICD, Group Clinical Director of Theranostics, and he is a Nuclear Medicine Physician.

Languages spoken

English, Italian



Murdoch (Oncology)
Murdoch (Oncology)

100 Murdoch Drive, Murdoch WA 6150 (access via St John of God Murdoch Hospital, Gate 3

-32.067130818740424, 115.84572533810733

Clinical interests in theranostics, molecular imaging and translational research.

Nat graduated in medicine from the University of Western Australia and then completed a fellowship in nuclear medicine at the University of Michigan. Apart from undergraduate science, research and medical degrees, he also holds masters degrees in medicine, oncology, health service management and business administration, and is currently completing an online masters in molecular oncology with the European School of Medical Oncology.

From 2001 - 2006, Nat was the inaugural Head of Western Australian PET/cyclotron service based at the Sir Charles Gairdner Hospital. In addition, Nat also held the Head of Department positions in Nuclear Medicine and Internal Medicine at Royal Perth Hospital and Fremantle Hospital.

Currently, Nat is an an adjunct clinical professor in Medicine at Curtin University and Notre Dame University Australia. He also works as a consultant nuclear physician and acute medicine physician at Fiona Stanley Hospital, and general physician at St John of God Hospital Murdoch.

With a track record in developing clinical and research services in both the public and private sectors, Nat is interested in clinical research in the areas of oncology and theranostics. Nat is the co-investigator on a number of grants, a principal investigator in several clinical trials, and a co-author on many peer reviewed publications, predominantly in the areas of oncology and theranostics.

In 2015, Nat founded Theranostics Australia, now fully owned by GenesisCare, where he remains in the position of group clinical director. He is committed to expanding the field of theranostics with GenesisCare in Australia and overseas.